Alexion to buy biopharmaceutical firm Portola in $1.41bn deal
Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn.
Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn.
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Eli Lilly has collaborated with Junshi Biosciences for the development of therapeutic antibodies to treat and prevent Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus.
AbCellera has secured a commitment of up to CAD175.6m ($124.3m) from the Government of Canada to discover solutions for Covid-19 and construct a manufacturing facility for antibody drugs.
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.
The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.
Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.
Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.
Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.